CD47 predominates over CD24 as a macrophage immune checkpoint in cancer.
Juliet Allen, Anna Meglan, Kyle Vaccaro, José Velarde, Victor Chen, Juliano Ribeiro, Jasmine Blandin, Sumeet Gupta, Ranjan Kumar Mishra, Raymond Ho, Jennifer A. Love, Ferenc Reinhardt, George W. Bell, Jin Chen, Robert A. Weinberg, , Kipp Weiskopf
This study identifies CD47 as a more effective macrophage immune checkpoint than CD24 in cancer and develops bispecific antibodies to enhance macrophage-mediated tumor killing.
bioRxiv · Nov 25, 2024 · PreprintCancer Biology